Nodofree Combi (Dorzolamide Hydrochloride, Timolol Maleate)

Dorzolamide blocks carbonic anhydrase enzymes in the ciliary body, reducing the formation of bicarbonate ions that drive aqueous humor production. This decrease in fluid secretion leads to lower intra‑ocular pressure, which is a key factor in managing glaucoma and ocular hypertension.

The dosing regimen is determined by the prescribing clinician based on the patient’s condition and response. Typically, one drop is instilled in each affected eye once or twice daily, but the exact frequency and duration must be individualized by a qualified healthcare professional.

Safety data for Dorzolamide/Timolol eye drops in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a physician.

Enquiries are submitted through the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Prostaglandin analogues such as latanoprost primarily increase uveoscleral outflow, whereas Nodofree Combi reduces aqueous humor production through two mechanisms—carbonic anhydrase inhibition and β‑blockade. The combination may be preferred when a patient requires additional pressure‑lowering effect or cannot tolerate prostaglandins.

Store the eye‑drop bottles at temperatures below 25 °C, in the original packaging, protected from light and moisture. Keep the container tightly closed when not in use and discard any solution that appears discolored or contaminated.

The solution is applied topically to the conjunctival sac. After washing hands, tilt the head back, pull down the lower eyelid to create a small pocket, and place one drop into the pocket without touching the tip of the bottle to the eye or surrounding tissues.

Serious adverse events include severe allergic reactions (angio‑edema or anaphylaxis), marked bradycardia or bronchospasm, and rare occurrences of corneal ulceration or significant visual loss. Patients should seek immediate medical attention if they experience any of these symptoms.

The product is contraindicated in patients with known hypersensitivity to dorzolamide, timolol, sulfonamides, or any component of the formulation. It should also be avoided in individuals with severe sinus bradycardia, second‑ or third‑degree heart block, uncontrolled asthma, or chronic obstructive pulmonary disease without medical supervision.